130 related articles for article (PubMed ID: 37234009)
1. Pharmacy Availability of Buprenorphine for Opioid Use Disorder Treatment in the US.
Weiner SG; Qato DM; Faust JS; Clear B
JAMA Netw Open; 2023 May; 6(5):e2316089. PubMed ID: 37234009
[TBL] [Abstract][Full Text] [Related]
2. Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden.
Kazerouni NJ; Irwin AN; Levander XA; Geddes J; Johnston K; Gostanian CJ; Mayfield BS; Montgomery BT; Graalum DC; Hartung DM
Drug Alcohol Depend; 2021 Jul; 224():108729. PubMed ID: 33932744
[TBL] [Abstract][Full Text] [Related]
3. Patient satisfaction with clinic-based medication pick up: Addressing pharmacy-level challenges to buprenorphine access.
Kolb E; Rueth M
J Opioid Manag; 2021; 17(7):77-86. PubMed ID: 34520029
[TBL] [Abstract][Full Text] [Related]
4. Expanded buprenorphine prescribing privileges: Sandbagging in the midst of the flood?
Brown JD; Nolte JL
Res Social Adm Pharm; 2018 Jun; 14(6):617-618. PubMed ID: 29525482
[No Abstract] [Full Text] [Related]
5. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.
Raisch DW; Fudala PJ; Saxon AJ; Walsh R; Casadonte P; Ling W; Johnson BA; Malkerneker U; Ordorica P; Williford WO; Sather MR
J Am Pharm Assoc (2003); 2005; 45(1):23-32. PubMed ID: 15730114
[TBL] [Abstract][Full Text] [Related]
6. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
Currie JM; Schnell MK; Schwandt H; Zhang J
JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
[TBL] [Abstract][Full Text] [Related]
7. Supportive alternate site provision of buprenorphine: Overcoming barriers and improving patient outcomes.
Khan A; Khan Q; Kolb E
J Subst Abuse Treat; 2021 Apr; 123():108256. PubMed ID: 33612191
[TBL] [Abstract][Full Text] [Related]
8. Pharmacy-based expansion of buprenorphine access.
Clark SA; Green TC; Rich JD
J Subst Use Addict Treat; 2024 Feb; 157():209195. PubMed ID: 37858795
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
[TBL] [Abstract][Full Text] [Related]
10. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
Cochran G; Bruneau J; Cox N; Gordon AJ
Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
[TBL] [Abstract][Full Text] [Related]
11. US pharmacy chains settle opioid lawsuits for $13bn.
Tanne JH
BMJ; 2022 Nov; 379():o2688. PubMed ID: 36347532
[No Abstract] [Full Text] [Related]
12. Federal and State Pharmacy Regulations and Dispensing Barriers to Buprenorphine Access at Retail Pharmacies in the US.
Qato DM; Watanabe JH; Clark KJ
JAMA Health Forum; 2022 Aug; 3(8):e222839. PubMed ID: 36218988
[TBL] [Abstract][Full Text] [Related]
13. Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment.
Stein BD; Saloner BK; Golan OK; Andraka-Christou B; Andrews CM; Dick AW; Davis CS; Sheng F; Gordon AJ
JAMA Health Forum; 2023 May; 4(5):e231102. PubMed ID: 37234015
[TBL] [Abstract][Full Text] [Related]
14. Trends in Buprenorphine Initiation and Retention in the United States, 2016-2022.
Chua KP; Nguyen TD; Zhang J; Conti RM; Lagisetty P; Bohnert AS
JAMA; 2023 Apr; 329(16):1402-1404. PubMed ID: 37097363
[TBL] [Abstract][Full Text] [Related]
15. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
[TBL] [Abstract][Full Text] [Related]
16. Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021.
Thakrar AP; Alexander GC; Saloner B
JAMA Netw Open; 2021 Dec; 4(12):e2138807. PubMed ID: 34905010
[TBL] [Abstract][Full Text] [Related]
17. The Howard Street Method: A Community Pharmacy-led Low Dose Overlap Buprenorphine Initiation Protocol for Individuals Using Fentanyl.
Noel M; Abbs E; Suen L; Samuel L; Dobbins S; Geier M; Soran CS
J Addict Med; 2023 Jul-Aug 01; 17(4):e255-e261. PubMed ID: 37579105
[TBL] [Abstract][Full Text] [Related]
18. Common elements in opioid use disorder guidelines for buprenorphine prescribing.
Atkinson TJ; Pisansky AJB; Miller KL; Yong RJ
Am J Manag Care; 2019 Mar; 25(3):e88-e97. PubMed ID: 30875177
[TBL] [Abstract][Full Text] [Related]
19. Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period.
Lembke A; Ottestad E; Schmiesing C
Pain Med; 2019 Mar; 20(3):425-428. PubMed ID: 29452378
[No Abstract] [Full Text] [Related]
20. Trends in Out-of-Pocket Costs for and Characteristics of Pharmacy-Dispensed Buprenorphine Medications for Opioid Use Disorder Treatment by Type of Payer, 2015 to 2020.
Strahan AE; Desai S; Zhang K; Guy GP
JAMA Netw Open; 2023 Feb; 6(2):e2254590. PubMed ID: 36763363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
